TickerFacts.

Keros Therapeutics, Inc. (KROS): Cash & Equivalents

Annual figures by period end, from SEC filings.

$287.42M
As of 2025-12-31
$257.61M
As of 2026-06-30
+1.0%
3-year compound annual growth
+1.6%
5-year compound annual growth
$559.93M2019-12-31: $7.02M2020-12-31: $265.88M2021-12-31: $230.04M2022-12-31: $279.05M2023-12-31: $331.15M2024-12-31: $559.93M2025-12-31: $287.42M$287.42M
2019-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$287.42M-48.7%2026-03-04, Balance as of period end
2024-12-31$559.93M+69.1%2026-03-04, Balance as of period end
2023-12-31$331.15M+18.7%2025-02-26, Balance as of period end
2022-12-31$279.05M+21.3%2025-02-26, Balance as of period end
2021-12-31$230.04M-13.5%2024-02-28, Balance as of period end
2020-12-31$265.88Mn/m2022-03-09, Balance as of period end
2019-12-31$7.02Mn/a2021-03-25, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Keros Therapeutics, Inc. (KROS)2025-12-31$287.42M-48.7%
Arcus Biosciences, Inc. (RCUS)2025-12-31$222.00M+48.0%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$184.84M+256.4%
Anaptysbio, Inc (ANAB)2025-12-31$238.20M+93.5%
Schrodinger, Inc. (SDGR)2025-12-31$230.52M+56.5%
Puma Biotechnology, Inc. (PBYI)2025-12-31$29.64M-57.2%
Arvinas, Inc. (ARVN)2025-12-31$142.90M+42.2%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$174.93M+141.9%
Harrow, Inc. (HROW)2025-12-31$72.93M+54.4%

Compare KROS, RCUS, AKBA, ANAB side by side · Screen every company in Pharmaceutical Preparations ↗